I hope research like this will someday uncover the real reasons for issues such as recognized metabolic syndrome features, joint discomfort, mood disorders, and cancer, which improve thanks to GLP-1 alternatives. Still, I don't think the cause lies in insufficient natural GLP-1 availability.
I saw a tweet laying out results from a large review of twelve thousand plus cases across seven cancer types. People on GLP-1 drugs showed lung cancer spread at roughly half the usual level. Breast cancer occurrence dropped by forty three percent. A different analysis of colon cancer found five year death rates at fifteen point five percent against thirty seven point one percent. The advantages look like they extend past weight reduction alone, and these agonists keep turning up additional benefits that feel pretty encouraging.